Quantcast

Latest Bextra Stories

2013-05-18 23:04:28

The personal injury law firm of d´Oliveira & Associates has issued an infographic on Stevens Johnson Syndrome, which details potential causes and serious conditions that may result from the syndrome. (PRWEB) May 18, 2013 According to the the Stevens Johnson Syndrome Foundation, Stevens Johnson Syndrome (SJS), also known as Toxic Epidermal Necrolysis, is a severe allergic reaction usually to medicine (i). The first signs of SJS involve flu-like symptoms but it can quickly advance...

2011-02-23 13:31:31

Analysis highlights cardiovascular risk of fluid retention New research shows that medications which have raised safety concerns over heart attack and stroke risks may not have gotten approval from the Food and Drug Administration (FDA) if the cardiovascular effects of fluid retention had been better understood. Fluid retention may explain the increased risk of heart attacks and strokes of medications such as Vioxx®, Bextra®, and...

2010-03-25 09:45:00

NEW YORK, March 25 /PRNewswire/ -- Grant & Eisenhofer, a leading shareholder and corporate governance law firm, was successful in upholding the admission of testimony against pharmaceutical giant Pfizer by six expert witnesses in a rare securities-related Daubert hearing. U.S. District Court Judge Laura Taylor Swain of the United States District Court for the Southern District of New York issued her written ruling on Monday, March 22. Grant & Eisenhofer is representing the class...

2009-10-16 16:41:00

BOSTON, Oct. 16 /PRNewswire-USNewswire/ -- PHARMACIA & UPJOHN COMPANY, INC., a subsidiary of Pfizer Inc. ("Pfizer") today was sentenced today in federal court for a felony violation of the Food, Drug & Cosmetic Act, for misbranding the drug, Bextra, with the intent to defraud or mislead. PHARMACIA & UPJOHN COMPANY, INC. was sentenced by United States District Judge Douglas P. Woodlock to pay a criminal fine of $1.195 billion and a criminal forfeiture of $105 million, for a...

2009-10-16 15:05:00

WASHINGTON, Oct. 16 /PRNewswire/ -- Pfizer Inc., through a wholly owned subsidiary, is expected to plead guilty to a felony today in federal district court in Boston as part of a plea agreement that includes a record-breaking $1.3 billion criminal fine for the illegal marketing of the painkiller Bextra for unsafe and unapproved uses. "This case exposed the total disregard a pharmaceutical company had for patients' lives by putting profits above all else," said Erika A. Kelton, a...

2009-09-02 10:35:00

Pfizer to Pay $2.3 Billion for Fraudulent Marketing WASHINGTON, Sept. 2 /PRNewswire-USNewswire/ -- American pharmaceutical giant Pfizer Inc. and its subsidiary Pharmacia & Upjohn Company Inc. (hereinafter together "Pfizer") have agreed to pay $2.3 billion, the largest health care fraud settlement in the history of the Department of Justice, to resolve criminal and civil liability arising from the illegal promotion of certain pharmaceutical products, the Justice Department announced...

2009-09-02 09:37:00

WASHINGTON, Sept. 2 /PRNewswire/ -- The decision by a Pfizer sales representative in Florida to file a whistleblower ("qui tam") lawsuit in 2003 kicked off the federal and state investigations that led to Pfizer's record-breaking $2.3 billion settlement today. "In the Army, I was expected to protect people at all costs," said the whistleblower, John Kopchinski, a West Point graduate and Gulf War veteran. "At Pfizer I was expected to increase profits at all costs, even when sales meant...

bd11f4ae31c913548199ad9644300111
2009-09-02 10:30:00

The U.S. Department of Justice said pharmaceutical giant Pfizer will pay a record $2.3 billion fine to settle fraudulent marketing of the painkiller Bextra. Bextra was pulled off the market in 2005. The case settled Wednesday involved Pfizer's marketing of the drug for uses not approved by the Food and Drug Administration. A company must specify the intended use of a product, the Department of Health and Human Services said in a release. Once approved, the drug may not be marketed or promoted...

2009-04-29 08:00:00

WASHINGTON, April 29 /PRNewswire-USNewswire/ -- A federal court in San Francisco has granted preliminary approval to a proposed settlement with Pfizer Inc. ("Pfizer") about the marketing of the prescription drugs Bextra and Celebrex. The settlement in the case called In re Bextra and Celebrex Marketing, Sales Practices, and Product Liability Litigation, No. 05-CV-01669, MDL No. 1699, pending in the United States District Court for the Northern District of California, will provide a Settlement...

2008-10-22 12:00:51

Pfizer Inc announced today that it has finalized agreements with 33 states and the District of Columbia to resolve claims primarily related to alleged promotional practices for Bextra, a medication Pfizer voluntarily withdrew from the United States market in 2005. Last week Pfizer announced agreements in principle to resolve these state claims, indicating that it would pay $60 million and adopt compliance measures as part of the settlement that complement policies and procedures previously...


Word of the Day
callithump
  • A somewhat riotous parade, accompanied with the blowing of tin horns, and other discordant noises; also, a burlesque serenade; a charivari.
'Callithump' is a back-formation of 'callithumpian,' a 'fanciful formation' according to the Oxford English Dictionary. However, the English Dialect Dictionary, says 'Gallithumpians' is a Dorset and Devon word from the 1790s that refers to 'a society of radical social reformers' or 'noisy disturbers of elections and meetings.'
Related